Quadrosilan
| Code | Size | Price |
|---|
| TAR-T28484-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Quadrosilan is a synthetic, nonsteroidal estrogen.
CAS:
4657-20-9
Formula:
C18H28O4Si4
Molecular Weight:
420.758
Purity:
0.98
SMILES:
C[Si]1(C)O[Si](C)(O[Si](C)(C)O[Si](C)(O1)c1ccccc1)c1ccccc1
References
1. Alfthan O, Andersson L, Esposti PL, Foss? SD, Gammelgaard PA, Gj?res JE, Isacson S, Rasmussen F, Ruutu M, von Schreeb T, Setterberg G, Strandell P, Strindberg B. Cisobitan in treatment of prostatic cancer. A prospective controlled multicentre study. Scand J Urol Nephrol. 1983;17(1):37-43. PubMed PMID: 6346476.
2. Collste L, Berlin T, von Garrelts B, Granberg I, Lewander R. Clinical trial of a new antigonadotropic substance, 2,6-cis-diphenylhexamethylcyclotetrasiloxane, in cancer of the prostate. A pilot study. Eur Urol. 1981;7(2):85-8. PubMed PMID: 7461008.
3. Sundwall A. Cisobitan--a new drug with anti-gonadotropic and anti-androgenic properties. Pharmacological effects. Scand J Urol Nephrol Suppl. 1980;55:121-5. PubMed PMID: 6938014.
4. Albanus L, Bj?rklund NE, Gustafsson B, J?nsson M. Forty days oral toxicity of 2,6-cis-diphenylhexamethylcyclotetrasiloxane (KABI 1774)in beagle dogs with special reference to effects on the male reproductive system. Acta Pharmacol Toxicol (Copenh). 1975;36(Suppl 3):93-130. PubMed PMID: 1080338.